Biologics have unique developmental challenges on their pathway to becoming a commercial product. Today’s biologics are developed utilizing a wide variety of modalities, including antibodies, peptides, enzymes, fusion proteins, antibody-drug conjugates, gene therapies and cellular therapies (e.g. CAR-Ts). While this breadth of modalities has opened up biologic development to new possibilities, it has also required innovation to overcome developmental hurdles. In biologics development, one of the most promising innovations is engineered micro- or nano-particle technology.